新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300519 新光药业

已收盘 10-10 15:00:00

{"stockData":{"symbol":"300519","market":"SZ","secType":"STK","nameCN":"新光药业","latestPrice":15.63,"timestamp":1760079795000,"preClose":15.48,"halted":0,"volume":2514303,"delay":0,"changeRate":0.0097,"floatShares":113999999,"shares":160000000,"eps":0.355,"marketStatus":"已收盘","change":0.15,"latestTime":"10-10 15:00:00","open":15.5,"high":15.76,"low":15.42,"amount":39332000,"amplitude":0.022,"askPrice":15.63,"askSize":138,"bidPrice":15.62,"bidSize":20,"shortable":0,"etf":0,"ttmEps":0.355,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1760319000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.48,"symbolType":"stock","openAndCloseTimeList":[[1760059800000,1760067000000],[1760072400000,1760079600000]],"highLimit":17.03,"lowLimit":13.93,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":160000000,"isCdr":false,"pbRate":3.04,"roa":"--","peRate":44.028169,"roe":"3.8%","epsLYR":0.31,"committee":0.169014,"marketValue":2501000000,"turnoverRate":0.022,"status":0,"floatMarketCap":1783000000},"requestUrl":"/m/hq/s/300519","defaultTab":"news","newsList":[{"id":"2568233494","title":"9月17日新光药业发布公告，股东减持36.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2568233494","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568233494?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:01","pubTimestamp":1758117695,"startTime":"0","endTime":"0","summary":"证券之星消息，9月17日新光药业发布公告《新光药业:关于公司持股5%以上股东股份减持计划届满的公告》，其股东嵊州市和丰投资股份有限公司于2025年9月16日合计减持36.1万股，占公司目前总股本的0.2256%，变动期间该股股价上涨0.61%，截止9月16日收盘报16.54元。股东增减持详情见下表：根据新光药业2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700040126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300519","BK0239"],"gpt_icon":0},{"id":"2567102109","title":"9月16日新光药业发布公告，股东减持123.89万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2567102109","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567102109?lang=zh_cn&edition=full","pubTime":"2025-09-16 20:01","pubTimestamp":1758024102,"startTime":"0","endTime":"0","summary":"证券之星消息，9月16日新光药业发布公告《新光药业:关于公司持股5%以上股东减持股份触及1%整倍数的公告》，其股东嵊州市和丰投资股份有限公司于2025年7月31日至2025年9月15日间合计减持123.89万股，占公司目前总股本的0.7743%，变动期间该股股价下跌0.96%，截止9月15日收盘报16.44元。股东增减持详情见下表：根据新光药业2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600034258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"gpt_icon":0},{"id":"2562763194","title":"新光药业（300519）2025年中报简析：净利润同比增长25.09%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2562763194","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562763194?lang=zh_cn&edition=full","pubTime":"2025-08-27 06:28","pubTimestamp":1756247302,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期新光药业发布2025年中报。截至本报告期末，公司营业总收入1.41亿元，同比下降3.6%，归母净利润3190.77万元，同比上升25.09%。本报告期新光药业盈利能力上升，毛利率同比增幅7.64%，净利率同比增幅29.77%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700008865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"gpt_icon":0},{"id":"2562381221","title":"新光药业股价微涨0.41% 上半年净利润同比增长25.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562381221","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562381221?lang=zh_cn&edition=full","pubTime":"2025-08-26 01:31","pubTimestamp":1756143070,"startTime":"0","endTime":"0","summary":"新光药业最新股价报17.10元，较前一交易日上涨0.41%。盘中最高触及17.23元，最低下探至16.96元，成交量为48923手，成交金额达0.84亿元。新光药业属于中药行业，公司主要从事中成药、化学药、保健食品的研发、生产和销售。公司8月25日披露的半年报显示，上半年实现营业收入1.41亿元，归属于上市公司股东的净利润3190.77万元，同比增长25.09%。基本每股收益为0.2元。从资金流向来看，8月25日主力资金净流出947.32万元，近五日主力资金累计净流出7487.12万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26013152680050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300519"],"gpt_icon":0},{"id":"2561186418","title":"股市必读：新光药业（300519）8月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2561186418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561186418?lang=zh_cn&edition=full","pubTime":"2025-08-22 02:20","pubTimestamp":1755800424,"startTime":"0","endTime":"0","summary":"截至2025年8月21日收盘，新光药业报收于17.16元，下跌1.15%，换手率5.28%，成交量6.03万手，成交额1.04亿元。董秘最新回复投资者： 董秘你好，公司主营业务是中成药，化学药，保健食品的研发，生产和销售。交易信息汇总8月21日，新光药业的资金流向显示主力资金净流出2624.77万元；游资资金净流入970.08万元；散户资金净流入1654.69万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200002059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300519","BK0132"],"gpt_icon":0},{"id":"2556809512","title":"新光药业：公司治疗肝病方面的药物主要有护肝片、金胆片、四季菜颗粒等","url":"https://stock-news.laohu8.com/highlight/detail?id=2556809512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556809512?lang=zh_cn&edition=full","pubTime":"2025-08-04 16:18","pubTimestamp":1754295505,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司治疗肝炎的药物有哪些 有没有研发新药新光药业回复：您好，感谢您对本公司的关注。公司治疗肝病方面的药物主要有：护肝片、金胆片、四季菜颗粒等。暂未涉及这方面的新药研发。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080400021205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","300519"],"gpt_icon":0},{"id":"2556809918","title":"新光药业：重点围绕新产品创新研发以及中药的二次开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2556809918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556809918?lang=zh_cn&edition=full","pubTime":"2025-08-04 16:18","pubTimestamp":1754295502,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司对中药后期研发有哪些布局 对创新药研发有什么进展新光药业回复：您好，感谢您对本公司的关注！公司在产品研发方面，重点围绕新产品创新研发以及中药的二次开发，致力于制备工艺的优化改进以及产品质量标准的提升研究。以不断丰富产品管线，拓展产品适应症，提升企业核心竞争力。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080400021185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","300519"],"gpt_icon":0},{"id":"2555600074","title":"新光药业：合作开发新药YHTKL进入工艺研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2555600074","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555600074?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:54","pubTimestamp":1753952081,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，贵公司有什研发中的创新药吗？新光药业回复：您好，感谢您对本公司的关注。如年报披露，报告期内，公司合作开发的新药经典名方“YHTKL”目前已进入工艺研究阶段。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073100026593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300519","BK0239"],"gpt_icon":0},{"id":"2548611268","title":"新光药业：本公司全国独家品种无糖型增液颗粒常年生产正常销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2548611268","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548611268?lang=zh_cn&edition=full","pubTime":"2025-07-02 16:42","pubTimestamp":1751445732,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问一下贵公司的产品增液颗粒在市场上没有销售，不知道为什么？是原材料涨价还是什么原因。不知何时可以恢复生产销售？新光药业回复：您好，感谢您对本公司的关注。本公司全国独家品种无糖型增液颗粒常年生产，正常销售。您或贵公司有需要，可与公司销售部门联系，联系电话：0575-83292166。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200026406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","300519"],"gpt_icon":0},{"id":"2539720478","title":"每周股票复盘：新光药业（300519）注销部分募集资金专户并永久补充流动资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2539720478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539720478?lang=zh_cn&edition=full","pubTime":"2025-05-31 11:04","pubTimestamp":1748660655,"startTime":"0","endTime":"0","summary":"截至2025年5月30日收盘，新光药业报收于15.0元，较上周的14.62元上涨2.6%。本周，新光药业5月30日盘中最高价报15.27元。“现代中药研发中心建设项目”进行结项，节余募集资金永久补充流动资金，并对相关募集资金专户进行销户处理。现代中药研发中心建设项目对应的募集资金专用账户已注销，节余募集资金1732967105元转至公司子公司新光医药科技基本户，用于永久补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053100009013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"gpt_icon":0},{"id":"2537164383","title":"每周股票复盘：新光药业（300519）分红4800万元，股权登记日为2025年5月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=2537164383","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537164383?lang=zh_cn&edition=full","pubTime":"2025-05-24 12:18","pubTimestamp":1748060296,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘，新光药业报收于14.62元，较上周的14.58元上涨0.27%。本周关注点公司公告汇总：新光药业2024年年度权益分派方案已获股东大会通过，将派发4800万元现金红利公司公告汇总新光药业2024年年度权益分派方案已获2025年5月13日召开的2024年度股东大会审议通过。本次权益分派股权登记日为2025年5月27日，除权除息日为2025年5月28日。A股股东现金红利将于2025年5月28日通过股东托管证券公司直接划入其资金账户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400011480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300519","BK0132"],"gpt_icon":0},{"id":"2537137851","title":"5月26日A股投资避雷针︱新光药业：股东和丰投资拟减持不超3%股份；金花股份：董事长收到证监会立案告知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2537137851","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537137851?lang=zh_cn&edition=full","pubTime":"2025-05-23 22:04","pubTimestamp":1748009078,"startTime":"0","endTime":"0","summary":"萃华珠宝股东龙凤拟减持不超3.00%股份；新光药业股东和丰投资拟减持不超3%股份；世纪恒通股东熔岩新机遇、熔岩新时代拟合计减持不超2.00%股份；远翔新材股东华兴创投拟减持不超5.00%股份；聚胶股份股东郑朝阳拟减持不超3.00%股份；恒锋信息控股股东、实际控制人终止协议转让公司部分股份；金花股份董事长收到证监会立案告知书","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052322044595008543&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052322044595008543&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0132","159982","399300","600080","BK0239","300519"],"gpt_icon":0},{"id":"2537139081","title":"新光药业(300519.SZ)股东和丰投资拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2537139081","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537139081?lang=zh_cn&edition=full","pubTime":"2025-05-23 20:47","pubTimestamp":1748004427,"startTime":"0","endTime":"0","summary":"新光药业(300519.SZ)发布公告，股东嵊州市和丰投资股份有限公司(“和丰投资...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/7.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/7.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1297116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","300519","BK0132"],"gpt_icon":0},{"id":"2537133930","title":"新光药业最新公告：和丰投资计划减持不超过3%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2537133930","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537133930?lang=zh_cn&edition=full","pubTime":"2025-05-23 19:11","pubTimestamp":1747998663,"startTime":"0","endTime":"0","summary":"新光药业(300519.SZ)公告称，持股5%以上股东和丰投资计划于本公告披露之日起15个交易日后的3个月内以集中竞价交易或大宗交易方式减持其持有的不超过480万股公司股份，即不超过公司总股本的3%。其中，以集中竞价方式减持不超过160万股（占总股本1%），以大宗交易方式减持不超过320万股（占总股本2%）。减持原因为股东个人资金安排需求。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300033531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"gpt_icon":0},{"id":"2531629888","title":"新光药业（300519）2025年一季报简析：净利润增7.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531629888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531629888?lang=zh_cn&edition=full","pubTime":"2025-04-29 06:16","pubTimestamp":1745878619,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期新光药业发布2025年一季报。根据财报显示，新光药业净利润增7.5%。截至本报告期末，公司营业总收入9325.01万元，同比下降7.26%，归母净利润2454.18万元，同比上升7.5%。本次财报公布的各项数据指标表现一般。然而去年的净利率为18.83%，算上全部成本后，公司产品或服务的附加值高。融资分红：公司上市9年以来，累计融资总额2.44亿元，累计分红总额5.36亿元，分红融资比为2.2。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900006740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"gpt_icon":0},{"id":"2530433559","title":"图解新光药业一季报：第一季度单季净利润同比增7.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530433559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530433559?lang=zh_cn&edition=full","pubTime":"2025-04-27 17:38","pubTimestamp":1745746713,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业2025年一季报显示，公司主营收入9325.01万元，同比下降7.26%；归母净利润2454.18万元，同比上升7.5%；扣非净利润2336.65万元，同比上升9.49%；负债率7.46%，投资收益81.53万元，财务费用-826.75万元，毛利率36.79%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042700007609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"gpt_icon":0},{"id":"2530748292","title":"新光药业(300519.SZ)发布一季度业绩，归母净利润2454.18万元，增长7.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530748292","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530748292?lang=zh_cn&edition=full","pubTime":"2025-04-27 16:25","pubTimestamp":1745742334,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新光药业(300519.SZ)发布2025年第一季度报告，该公司营业收入为9325.01万元，同比减少7.26%。归属于上市公司股东的净利润为2454.18万元，同比增长7.50%。归属于上市公司股东的扣除非经常性损益的净利润为2336.65万元，同比增长9.49%。基本每股收益为0.15元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300519"],"gpt_icon":0},{"id":"2528852040","title":"【新光药业(300519.SZ)发布2024年度业绩，归母净利润5039万元，下降21.70%】新光药业(300519.SZ)发布2024年年度报告，该公司营业收入为2.68亿元，同比减少1.01%。归属于上市公司股东的净利润为5039万元，同比减少21.70%。归属于上市公司股东的扣除非经常性损益的净利润为4539.4万元，同比减少24.50%。基本每股收益为0.31元。此外，拟向全体股东每10股派发现金红利3.00元(含税)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528852040","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528852040?lang=zh_cn&edition=full","pubTime":"2025-04-20 17:30","pubTimestamp":1745141452,"startTime":"0","endTime":"0","summary":"新光药业(300519.SZ)发布2024年年度报告，该公司营业收入为2.68亿元，同比减少1.01%。归属于上市公司股东的净利润为5039万元，同比减少21.70%。归属于上市公司股东的扣除非经常性损益的净利润为4539.4万元，同比减少24.50%。基本每股收益为0.31元。此外，拟向全体股东每10股派发现金红利3.00元(含税)。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/20173049695047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300519"],"gpt_icon":0},{"id":"2514069949","title":"新光药业收盘下跌1.54%，滚动市盈率49.32倍，总市值21.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514069949","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514069949?lang=zh_cn&edition=full","pubTime":"2025-02-25 18:11","pubTimestamp":1740478305,"startTime":"0","endTime":"0","summary":"2月25日，新光药业今日收盘13.39元，下跌1.54%，滚动市盈率PE达到49.32倍，总市值21.42亿元。从行业市盈率排名来看，公司所处的中药行业市盈率平均38.11倍，行业中值24.67倍，新光药业排名第54位。资金流向方面，2月25日，新光药业主力资金净流出415.71万元，近5日总体呈流出状态，5日共流出797.07万元。最新一期业绩显示，2024年三季报，公司实现营业收入2.16亿元，同比0.05%；净利润3778.24万元，同比-35.63%，销售毛利率35.08%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25181148375901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","300519","BK0132"],"gpt_icon":0},{"id":"2501874932","title":"1月8日新光药业发布公告，其股东减持144.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2501874932","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501874932?lang=zh_cn&edition=full","pubTime":"2025-01-08 18:01","pubTimestamp":1736330489,"startTime":"0","endTime":"0","summary":"证券之星消息，1月8日新光药业发布公告《新光药业:关于持股5%以上股东减持股份比例达到1%的公告》，其股东嵊州市和丰投资股份有限公司于2024年4月9日至2025年1月6日间合计减持144.6万股，占公司目前总股本的0.9038%，变动期间该股股价上涨10.63%，截止1月6日收盘报13.22元。股东增减持详情见下表：根据新光药业2024年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010800032168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1760136098925,"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0613},{"period":"3month","weight":0.0149},{"period":"6month","weight":0.2505},{"period":"1year","weight":0.0738},{"period":"ytd","weight":0.2025}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.1102},{"period":"6month","weight":0.2034},{"period":"1year","weight":0.1802},{"period":"ytd","weight":0.1627}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江新光药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14146人(较上一季度减少8.56%)","perCapita":"8065股","listingDate":"2016-06-24","address":"浙江省绍兴市嵊州市剡湖街道环城西路25号","registeredCapital":"16000万元","survey":"　　浙江新光药业股份有限公司的主营业务是中成药、化学药、保健食品的研发、生产和销售。公司的主要产品是黄芪生脉饮、伸筋丹胶囊、西洋参口服液、黄芪生脉颗粒、增液颗粒、慢支固本颗粒。公司主导产品黄芪生脉饮多次获得“浙江省名牌产品”称号和“中国中药名牌产品”称号，为公司赢得了良好的品牌形象。“新光”商标多次荣获“浙江省著名商标”称号。黄芪生脉饮入选浙江省首批“浙产名药”。公司拥有核心自主知识产权11项，其中以自主研发方式获得的发明专利6项。","listedPrice":12.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新光药业(300519)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新光药业,300519,新光药业股票,新光药业股票老虎,新光药业股票老虎国际,新光药业行情,新光药业股票行情,新光药业股价,新光药业股市,新光药业股票价格,新光药业股票交易,新光药业股票购买,新光药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新光药业(300519)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}